1196-09-4

Basic information

• Product Name: 5-BroMo-3-Methyl-benzo[b]thiophene
• Synonyms: 5-broMo-3-Methyl-1-benzothiophene;5-Bromo-3-methylbenzothiophene;5-Bromo-3-methy-1-benzothiophene
• CAS NO: 1196-09-4
• Molecular Formula: C₉H₇BrS
• Molecular Weight: 227.12088
• Mol File: 1196-09-4.mol
• Article Data: 12

Chemical Properties

• Melting Point: 40-41℃
• Boiling Point: 302.321 °C at 760 mmHg
• Flash Point: 136.639 °C
• Appearance: /
• Density: 1.561
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.68
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 5-BroMo-3-Methyl-benzo[b]thiophene(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BroMo-3-Methyl-benzo[b]thiophene(1196-09-4)
• EPA Substance Registry System: 5-BroMo-3-Methyl-benzo[b]thiophene(1196-09-4)

Safety Data

• Hazardous Substances Data: 1196-09-4(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Heterocyclic Chemistry, 21, p. 1069, 1984 DOI: 10.1002/jhet.5570210430

InChI:InChI=1/C9H7BrS/c1-6-5-11-9-3-2-7(10)4-8(6)9/h2-5H,1H3

Upstream product

• 106-53-6 para-bromobenzenethiol 
• 1200-12-0 1-(4-bromophenylthio)propan-2-one 

Downstream Products

• 1365721-89-6 ethyl 3-{[(5-bromo-3-methyl-1-benzothiophen-2-yl)sulfonyl]amino}benzoate 
• 1365720-77-9 3-{[(3-methyl-5-morpholin-4-yl-1-benzothiophen-2-yl)sulfonyl]amino}benzoic acid 
• 1365719-47-6 3-{[(5-bromo-3-methyl-1-benzothien-2-yl)sulfonyl]amino}benzoic acid 
• 1757-24-0 5-bromo-3-bromomethylbenzothiophene 
• 19404-23-0 3-methyl-benzo[b]thiophene-5-carbonitrile 
• 22964-00-7 N-2-(5-bromobenzo[b]thiophen-3-yl)ethylamine hydrochloride 
• 23799-61-3 5-bromo-3-cyanomethylbenzo[b]thiophene 
• 51828-35-4 1-(5-bromo-3-methylbenzo[b]thiophen-2-yl)ethanone 

Relevant articles and documents

Benzo[b]thiophene derivatives. XXVIII. 5-Bromo-3-benzo[b]thienylalanine and derivatives

A potential inhibitor of gelation of sickle hemoglobin, 5-bromo-3-benzo[b]thienylalanine, has been synthesized along with several derivatives. Several hydrolytic pathways from the intermediate ethyl 5-bromo-3-benzo[b]thienylformamidomalonate have been exa

GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7- nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C17,20-lyase inhibitors.

Benzothiophene containing Rho kinase inhibitors: Efficacy in an animal model of glaucoma

We identified a new benzothiophene containing Rho kinase inhibitor scaffold in an ultra high-throughput enzymatic activity screen. SAR studies, driven by a novel label-free cellular impedance assay, were used to derive 39, which substantially reduced intr